

Caroline Even

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11955086/publications.pdf>

Version: 2024-02-01

38
papers

7,085
citations

394390

19
h-index

289230

40
g-index

40
all docs

40
docs citations

40
times ranked

9386
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
2	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
3	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017, 7, 586-595.	9.4	554
4	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 4050-4056.	1.6	335
5	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
6	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	7.1	235
7	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2019, 107, 142-152.	2.8	208
8	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	7.0	115
9	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2019, 121, 123-129.	2.8	115
10	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC). <i>Journal of Clinical Oncology</i> , 2017, 35, 463-475.	10.7	95
11	Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015, 51, 742-750.	2.8	86
12	Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. <i>Haematologica</i> , 2011, 96, 337-341.	3.5	72
13	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	3.7	70
14	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	4.5	62
15	Avelumab+cetuximab+radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). <i>European Journal of Cancer</i> , 2020, 141, 21-29.	2.8	48
16	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 62, 114-121.	1.5	43
17	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6413-6423.	7.0	37
18	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	2.8	33

#	ARTICLE	IF	CITATIONS
19	Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?. <i>European Journal of Cancer</i> , 2018, 94, 61-69.	2.8	29
20	Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab. <i>Radiotherapy and Oncology</i> , 2018, 128, 467-471.	0.6	18
21	PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6086-6086.	1.6	18
22	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	3.7	18
23	Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy. <i>Laryngoscope</i> , 2020, 130, E144-E150.	2.0	15
24	Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 159, 125-132.	2.8	11
25	Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 2267-2271.	1.6	10
26	Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma. <i>Anticancer Research</i> , 2016, 36, 6625-6630.	1.1	10
27	Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 168, 40-45.	0.6	10
28	High incidence of cetuximab-related infusion reactions in head and neck patients. <i>ESMO Open</i> , 2018, 3, e000346.	4.5	8
29	New approaches in salivary gland carcinoma. <i>Current Opinion in Oncology</i> , 2019, 31, 169-174.	2.4	8
30	Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6024-6024.	1.6	8
31	Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. <i>Laryngoscope</i> , 2017, 127, 1791-1796.	2.0	7
32	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. <i>Radiotherapy and Oncology</i> , 2021, 154, 125-127.	0.6	7
33	Efficacy and safety of immune checkpoint inhibitors in elderly patients (>=70 years) with squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2021, 157, 190-197.	2.8	6
34	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022, 2, 39-48.	1.7	4
35	Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility?. <i>Oral Oncology</i> , 2019, 90, 13-16.	1.5	2
36	Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait. <i>European Journal of Cancer</i> , 2021, 145, 155-157.	2.8	2

#	ARTICLE	IF	CITATIONS
37	Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. <i>Oncotarget</i> , 2017, 8, 51830-51839.	1.8	2
38	Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2021, 112, 104984.	1.5	1